← Leaderboards
Nabeel Bardeesy
Massachusetts General Hospital
$18,920,034
Attributed
$26,292,190
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,389,276 · 17
By mechanism
R01$19,545,384 · 9
P50$16,637,583 · 3
P01$4,417,309 · 3
K01$783,000 · 1
R13$6,000 · 1
Top collaborators
- Raul Mostoslavsky7 shared
- David Tsai Ting7 shared
- Joseph Avruch5 shared
- William R Sellers5 shared
- Kwok Kin Wong5 shared
- Kimberly A. Kelly4 shared
- Adam Joel Bass3 shared
- Sandra W Ryeom2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Guillermo J. Tearney$42,608,505
- Chin Hur$15,301,977
- Umar Mahmood$14,709,251
- Raul Mostoslavsky$11,553,356
- David Tsai Ting$4,336,400
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsSignal TransductionIn VivoMutationResponseCellsProgramsPathway InteractionsSpecimenBaseMutantGeneticBiologicalMolecularMediatingGenetically Engineered MouseGrowthResistanceInsightPhenotypeIn VitroGenerationsMalignant Neoplasm Of Pancreas
Grant awards (66)
Project 2-Identifying and exploiting metabolic vulnerabilities in PDAC$941,562
P01 · FY2025 · CA · contact PI
Harnessing mutant IDH1 as a therapeutic target in liver cancer and other solid malignancies$693,781
R01 · FY2025 · CA · contact PI
Targeting FGFR Alterations in Gastroesophageal Cancer$680,532
R01 · FY2025 · CA
Functions of mutant IDH in cholangiocarcinoma$653,532
R01 · FY2025 · CA · contact PI
Targeting FGFR Alterations in Gastroesophageal Cancer$716,314
R01 · FY2024 · CA
Project 2-Identifying and exploiting metabolic vulnerabilities in PDAC$650,399
P01 · FY2024 · CA · contact PI
Functions of mutant IDH in cholangiocarcinoma$620,855
R01 · FY2024 · CA · contact PI
Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer$2,248,301
P50 · FY2023 · CA
Project 2-Identifying and exploiting metabolic vulnerabilities in PDAC$684,630
P01 · FY2023 · CA · contact PI
Functions of mutant IDH in cholangiocarcinoma$653,532
R01 · FY2023 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$562,581
R01 · FY2023 · CA
Project 2 - Exploiting FGF Receptor Signaling Dependence in Liver Cancer Therapy$316,200
P50 · FY2023 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$233,789
R01 · FY2023 · CA
2023 Pancreatic Diseases Gordon Research Conference and Gordon Research Seminar$6,000
R13 · FY2023 · CA · contact PI
Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer$2,157,311
P50 · FY2022 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.$663,862
R01 · FY2022 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$562,581
R01 · FY2022 · CA
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics$470,621
R01 · FY2022 · CA · contact PI
Project 2 - Exploiting FGF Receptor Signaling Dependence in Liver Cancer Therapy$357,138
P50 · FY2022 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$127,680
R01 · FY2022 · CA
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics$116,466
R01 · FY2022 · CA · contact PI
Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer$1,547,949
P50 · FY2021 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.$677,442
R01 · FY2021 · CA · contact PI
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics$599,069
R01 · FY2021 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$574,063
R01 · FY2021 · CA
Project 2 - Exploiting FGF Receptor Signaling Dependence in Liver Cancer Therapy$176,809
P50 · FY2021 · CA · contact PI
Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer$2,237,511
P50 · FY2020 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.$677,471
R01 · FY2020 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$574,063
R01 · FY2020 · CA
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics$480,226
R01 · FY2020 · CA · contact PI
Project 2: Role of lysosomal scavenging in PDAC metabolism$416,968
P01 · FY2020 · CA · contact PI
Project 2 - Exploiting FGF Receptor Signaling Dependence in Liver Cancer Therapy$354,650
P50 · FY2020 · CA · contact PI
Functions of the LKB1 tumor suppressor in control in metabolism and epigentics$62,951
R01 · FY2020 · CA · contact PI
Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer$2,450,827
P50 · FY2019 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.$657,955
R01 · FY2019 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$574,063
R01 · FY2019 · CA
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics$465,818
R01 · FY2019 · CA · contact PI
Project 2: Role of lysosomal scavenging in PDAC metabolism$412,603
P01 · FY2019 · CA · contact PI
Project 2 - Exploiting FGF Receptor Signaling Dependence in Liver Cancer Therapy$335,700
P50 · FY2019 · CA · contact PI
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.$726,766
R01 · FY2018 · CA · contact PI
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics$480,226
R01 · FY2018 · CA · contact PI
Project 2: Role of lysosomal scavenging in PDAC metabolism$429,875
P01 · FY2018 · CA · contact PI
SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER$2,293,187
P50 · FY2017 · CA
Project 2: Role of lysosomal scavenging in PDAC metabolism$292,025
P01 · FY2017 · CA · contact PI
SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER$2,162,000
P50 · FY2016 · CA
Project 2: Role of lysosomal scavenging in PDAC metabolism$589,247
P01 · FY2016 · CA · contact PI
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppression$575,773
R01 · FY2014 · CA
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppression$574,756
R01 · FY2013 · CA
TGF-beta Signaling in Pancreatic Cancer$326,141
R01 · FY2013 · CA · contact PI
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo$325,984
R01 · FY2013 · EB
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppression$629,737
R01 · FY2012 · CA
TGF-beta Signaling in Pancreatic Cancer$346,958
R01 · FY2012 · CA · contact PI
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo$345,912
R01 · FY2012 · EB
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppression$648,642
R01 · FY2011 · CA
TGF-beta Signaling in Pancreatic Cancer$346,958
R01 · FY2011 · CA · contact PI
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo$346,127
R01 · FY2011 · EB
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppression$686,752
R01 · FY2010 · CA
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo$372,465
R01 · FY2010 · EB
TGF-beta Signaling in Pancreatic Cancer$1
R01 · FY2010 · CA · contact PI
TGF-beta Signaling in Pancreatic Cancer$357,363
R01 · FY2009 · CA · contact PI
Mouse Model of Pancreatic Cancer Progression-Maintenance$162,540
K01 · FY2009 · CA · contact PI
TGF-beta Signaling in Pancreatic Cancer$355,576
R01 · FY2008 · CA · contact PI
Mouse Model of Pancreatic Cancer Progression-Maintenance$161,730
K01 · FY2008 · CA · contact PI
Mouse Model of Pancreatic Cancer Progression-Maintenance$160,920
K01 · FY2007 · CA · contact PI
Mouse Model of Pancreatic Cancer Progression-Maintenance$160,110
K01 · FY2006 · CA · contact PI
Mouse Model of Pancreatic Cancer Progression-Maintenance$137,700
K01 · FY2005 · CA